Array
(
[Ovarian Cancer] => Array
(
[Austin] => https://www.survivornet.com/austin/
[Baltimore] => https://www.survivornet.com/baltimore/
[Charlotte] => https://www.survivornet.com/charlotte/
[Cleveland] => https://www.survivornet.com/cleveland/
[Columbus] => https://www.survivornet.com/columbus/
[Dallas / Ft. Worth] => https://www.survivornet.com/dallas-ftworth/
[Denver] => https://www.survivornet.com/denver/
[Detroit] => https://www.survivornet.com/detroit/
[Indianapolis] => https://www.survivornet.com/indianapolis-ovarian-cancer/
[Louisville] => https://www.survivornet.com/louisville/
[Memphis] => https://www.survivornet.com/memphis/
[Minneapolis] => https://www.survivornet.com/minneapolis/
[Nashville] => https://www.survivornet.com/nashville/
[Phoenix] => https://www.survivornet.com/phoenix/
[Portland] => https://www.survivornet.com/portland/
[Salt Lake City] => https://www.survivornet.com/salt-lake-city/
[San Antonio] => https://www.survivornet.com/san-antonio/
[San Diego] => https://www.survivornet.com/san-diego/
[San Francisco] => https://www.survivornet.com/san-francisco/
[San Jose] => https://www.survivornet.com/san-jose/
[Seattle] => https://www.survivornet.com/seattle/
) [Multiple Myeloma] => Array
(
[Ann Arbor] => https://www.survivornet.com/ann-arbor-michigan-multiple-myeloma-treatment/
[Miami] => https://www.survivornet.com/miami-florida-multiple-myeloma-treatment/
[Phoenix] => https://www.survivornet.com/phoenix-arizona-multiple-myeloma-treatment/
) [Glioma] => Array
(
[Midwest] => https://www.survivornet.com/midwest/
[Mountain States] => https://www.survivornet.com/glioma-mountain-states/
[Southeast] => https://www.survivornet.com/southeast/
) )
An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors Summary To determine the feasibility and safety of administering YM155 in combination with docetaxel
View Full Description Full Description This clinical trial is designed to include two parts: Part 1: Assessment of feasibility and safety of administering YM155 in combination with docetaxel and prednisone in subjects with hormone refractory prostate cancer (HRPC) [ ENROLLMENT COMPLETED ] Part 2: Assessment of feasibility and safety of administering YM155 in combination with docetaxel in subjects with solid tumors (except HRPC). This registration has been updated to reflect the design requirements of PART 2.
View Eligibility Criteria Eligibility Criteria Inclusion Criteria: Part 1: Male subjects with histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiological evidence of metastatic disease. Part 2: Subjects with histologically and cytologically confirmed solid tumors with measurable disease (except HRPC). Exclusion Criteria: Radiation therapy within 4 weeks of the start of study drug
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
San Antonio Texas, 78229, United States
How clear is this clinincal trial information?
Sign Up Sign up now for access to powerful tools, top experts, and customized information to help you fight cancer.
Personalized content tailored to your profile and disease type Access exclusive patient guides Breaking treatment information and expert perspectives and more... Sign Up Now Already have an account? Sign In
Sign Up Already have an account? Sign In
Sign In Don't have an account? Sign Up
Password reset is unavailable because your account was created using 'Sign Up with Google. To continue, please use the Google sign-in button below. Don't have an account? Sign Up